Rita Angélica Pineda-Sic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rita Angélica Pineda-Sic has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Dionicio Angel Galarza-Delgado
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
5 shared publications - Griselda Serna-Peña
Rheumatology Department, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Monterrey, México
3 shared publications - Jesus Alberto Cardenas-De la Garza
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
3 shared publications - Miguel Ángel Villarreal-Alarcón
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
2 shared publications - Sergio Andrés Castillo Torres
Neurology Service, Department of Internal Medicine, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Mexico
2 shared publications - Ana Sofía Leal-Bramasco
Hospital Universitario “Dr. José Eleuterio Gonzalez”, Monterrey, Mexico
1 shared publication
Latest Publications
- Open Access
- 30 November 2024
- Published by Facultad de Medicina de la Universidad Francisco Marroquin in Revista de la Facultad de Medicina
- Vol. 2 (2) , 42-49
Perniosis lúpica: Un reporte de caso
La perniosis lúpica es una forma rara de lupus eritematoso cutáneo. Esta se caracteriza por la presencia de pápulas eritematovioláceas que se presentan como consecuencias a cambios de temperatura. Observación clínica: Paciente masculino de 23 años con historia de pápulas violáceas en rostro, manos y pies pruriginosas posterior a episodio de vómitos. ANA: 2; Anti-Smith: 3.8 U/mL, Anti-RO: 25 U/mL. En histología se observó dermatitis de interfase, infiltrado perivascular de predominio linfocitico y focos de paniculitis septolobular difusa. Conclusión: La detección temprana de la perniosis lúpica permite brindar tratamiento local y farmacológico para evitar complicaciones a largo plazo como necrosis o infecciones.
- 30 November 2024
- Published by Facultad de Medicina de la Universidad Francisco Marroquin in Revista de la Facultad de Medicina
- Vol. 2 (2) , 42-49
Open AccessPerniosis lúpica: Un reporte de caso
La perniosis lúpica es una forma rara de lupus eritematoso cutáneo. Esta se caracteriza por la presencia de pápulas eritematovioláceas que se presentan como consecuencias a cambios de temperatura. Observación clínica: Paciente masculino de 23 años con historia de pápulas violáceas en rostro, manos y pies pruriginosas posterior a episodio de vómitos. ANA: 2; Anti-Smith: 3.8 U/mL, Anti-RO: 25 U/mL. En histología se observó dermatitis de interfase, infiltrado perivascular de predominio linfocitico y focos de paniculitis septolobular difusa. Conclusión: La detección temprana de la perniosis lúpica permite brindar tratamiento local y farmacológico para evitar complicaciones a largo plazo como necrosis o infecciones.
- Open Access
- 1 October 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (10) , e201
Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al
- 1 October 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (10) , e201
Open AccessEducation and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al
- Open Access
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (6) , e85
Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (6) , e85
Open AccessTreatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience
- Open Access
- 24 November 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (3) , 1197-1199
Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy
- 24 November 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (3) , 1197-1199
Open AccessCharacteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy
- 14 August 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (10) , 1717-1724
Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by multi-organ symptomatology. 16% of the patients with autoimmune thrombocytopenia have SLE and are associated with high mortality. Intravenous methylprednisolone or high-dose steroids are the first-line treatments in those patients who experienced life-threatening bleeding or have a severely low platelet count, whereas a second line includes splenectomy, as well as other immunosuppressive agents as monotherapy or combined therapy, including azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil. However, response rates of these therapies vary considerably. Rituximab (RTX) became a useful tool in the treatment of autoimmune diseases, due to the decrease of autoantibodies production. In addition, there is evidence that low doses of RTX (100 mg IV per week for 4 weeks) can have a similar effect compared to the standard dose. The objective of this study was to describe the response to low doses of RTX in patients with lupus-induced thrombocytopenia. We present a report of four female patients with newly diagnosed SLE, accompanied by purpuric syndrome and severe thrombocytopenia (< 30 × 109/L) as the clinical debut that was refractory to glucocorticoids (GC) therapy and treated with low doses of RTX. By week 5, complete response (> 100 × 109/L) was achieved in two patients, partial response (> 50 × 109/L) in 1 patient, and no response in one patient. There is little information on the treatment of SLE-associated autoimmune thrombocytopenia. The most extensive study found at the time of our search was the study of 10 Asian patients. They found that 80% of the patients responded by week four and maintained until week 24 of follow-up. At week 36, a follow-up for two patients showed relapse; this occurred on patients with the most disease duration (> 5 years) and was associated with a lower response rate. In contrast, our study with four patients found that half of them presented a complete response: one patient added concomitant therapy with azathioprine (AZA) and another patient without the concomitant therapy. A third patient with a partial improvement, this was seen by week five of treatment. Moreover, a fourth patient who did not have a response by week five of treatment presented a clinical response in subsequent appointments with a count of > 100 at week 24. Those patients who required concomitant use of AZA were patients who had positive antiphospholipid serology. The use of low-dose RTX for the management of severe thrombocytopenia refractory to GC in patients with SLE has a good response. It could be a safe, economical, and effective therapy.
- 14 August 2020
- Published by Springer Nature in Rheumatology International
- Vol. 40 (10) , 1717-1724
Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by multi-organ symptomatology. 16% of the patients with autoimmune thrombocytopenia have SLE and are associated with high mortality. Intravenous methylprednisolone or high-dose steroids are the first-line treatments in those patients who experienced life-threatening bleeding or have a severely low platelet count, whereas a second line includes splenectomy, as well as other immunosuppressive agents as monotherapy or combined therapy, including azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil. However, response rates of these therapies vary considerably. Rituximab (RTX) became a useful tool in the treatment of autoimmune diseases, due to the decrease of autoantibodies production. In addition, there is evidence that low doses of RTX (100 mg IV per week for 4 weeks) can have a similar effect compared to the standard dose. The objective of this study was to describe the response to low doses of RTX in patients with lupus-induced thrombocytopenia. We present a report of four female patients with newly diagnosed SLE, accompanied by purpuric syndrome and severe thrombocytopenia (< 30 × 109/L) as the clinical debut that was refractory to glucocorticoids (GC) therapy and treated with low doses of RTX. By week 5, complete response (> 100 × 109/L) was achieved in two patients, partial response (> 50 × 109/L) in 1 patient, and no response in one patient. There is little information on the treatment of SLE-associated autoimmune thrombocytopenia. The most extensive study found at the time of our search was the study of 10 Asian patients. They found that 80% of the patients responded by week four and maintained until week 24 of follow-up. At week 36, a follow-up for two patients showed relapse; this occurred on patients with the most disease duration (> 5 years) and was associated with a lower response rate. In contrast, our study with four patients found that half of them presented a complete response: one patient added concomitant therapy with azathioprine (AZA) and another patient without the concomitant therapy. A third patient with a partial improvement, this was seen by week five of treatment. Moreover, a fourth patient who did not have a response by week five of treatment presented a clinical response in subsequent appointments with a count of > 100 at week 24. Those patients who required concomitant use of AZA were patients who had positive antiphospholipid serology. The use of low-dose RTX for the management of severe thrombocytopenia refractory to GC in patients with SLE has a good response. It could be a safe, economical, and effective therapy.
- Open Access
- 23 June 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (10) , 3141-3142
Diplopia and ocular pain due to orbital myositis
- 23 June 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (10) , 3141-3142
Open AccessDiplopia and ocular pain due to orbital myositis
- Top Cited PapersOpen Access
- 16 January 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1
Intramedullary spinal cord neurocysticercosis presenting as Brown-Séquard syndrome
Cysticercosis is a parasitic disease caused by the larval stage of Taenia Solium. Involvement of the central nervous system by this tapeworm is endemic in developing countries. However, isolated spinal involvement by Taenia Solium is uncommon and having clinical presentation of Brown-Séquard syndrome is even rarer. A 43-year-old male who came to the emergency department with clinical presentation of complete Brown-Séquard syndrome. Computed tomography scan of the brain was normal. Magnetic resonance imaging of the thoracic spine revealed an intramedullary mass of the spinal cord at C-7/T-l level. Patient underwent surgery that revealed a cystic lesion and was resected. Histopathological report confirmed the diagnosis of neurocysticercosis. Postoperatively, oral steroid therapy and a four week course of albendazol were administered. Intramedullary neurcysticercosis represents a diagnostic challenge and should be considered in intramedullary lesions in settings where Taenia solium is endemic. Clinical, pathophysiological and diagnostic aspects of spinal cord intramedullary neurocysticercosis are discussed.
- 16 January 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1
Top Cited PapersOpen AccessIntramedullary spinal cord neurocysticercosis presenting as Brown-Séquard syndrome
Cysticercosis is a parasitic disease caused by the larval stage of Taenia Solium. Involvement of the central nervous system by this tapeworm is endemic in developing countries. However, isolated spinal involvement by Taenia Solium is uncommon and having clinical presentation of Brown-Séquard syndrome is even rarer. A 43-year-old male who came to the emergency department with clinical presentation of complete Brown-Séquard syndrome. Computed tomography scan of the brain was normal. Magnetic resonance imaging of the thoracic spine revealed an intramedullary mass of the spinal cord at C-7/T-l level. Patient underwent surgery that revealed a cystic lesion and was resected. Histopathological report confirmed the diagnosis of neurocysticercosis. Postoperatively, oral steroid therapy and a four week course of albendazol were administered. Intramedullary neurcysticercosis represents a diagnostic challenge and should be considered in intramedullary lesions in settings where Taenia solium is endemic. Clinical, pathophysiological and diagnostic aspects of spinal cord intramedullary neurocysticercosis are discussed.